Report cover image

Australia & New Zealand Healthcare CROs Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, Clinical), By Service, By Therapeutic Area, By End-use, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Oct 28, 2025
Length 120 Pages
SKU # GV20575182

Description

Australia & New Zealand Healthcare CROs Market Summary

The Australia & New Zealand healthcare CROs market size was estimated at USD 1.33 billion in 2024 and is projected to reach USD 3.35 billion by 2033, growing at a CAGR of 11.02% from 2025 to 2033. Supportive regulatory and ethical frameworks, government incentives and investment in R&D and advanced infrastructure and diverse patient pool are some of the key factors driving market growth.

The regulatory frameworks is anticipated to drive the clinical research activities in the Australia and New Zealand market. For instance, in New Zealand, it takes approximately 6.5 weeks to obtain regulatory approval and about 5 weeks for ethics approval. In Australia, the average time for regulatory approval is around 1 week, while ethics approval typically takes about 8 weeks, indicating the efficient yet different timelines for clinical trial governance in both nations. Swift ethics approval processes, standardized trial protocols, and well-recognized organizations such as the Therapeutic Goods Administration (TGA) and Medsafe help minimize start-up delays and improve adherence to ICH-GCP standards. This clear regulatory environment draws in global biopharmaceutical and medical device firms that are in search of consistent, high-quality research settings.

In addition, New Zealand has become a preferred destination for early-phase and adaptive clinical trials due to its rapid regulatory timelines, high-quality data standards, and cost-efficient trial execution. As a result, these regions have become preferred destinations for early-phase and adaptive clinical trials. This supportive framework lowers development costs and strengthens partnerships between sponsors and CROs, thereby expanding the healthcare contract research organization outlook.

Australia & New Zealand Healthcare CROs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Australia & New Zealand healthcare CROs market report based on type, service, therapeutic area, and end-use.
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead Optimization
  • Pre-clinical
  • Clinical
  • Phase I Trial Services
  • Phase II Trial Services
  • Phase III Trial Services
  • Phase IV Trial Services
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Project Management/Clinical Supply Management
  • Data Management
  • Regulatory/Medical Affairs
  • Medical Writing
  • Clinical Monitoring
  • Quality Management/ Assurance
  • Bio-statistics
  • Investigator Payments
  • Laboratory
  • Sterility Testing
  • Container/Closure Testing
  • Extractables and Leachable Testing
  • Environmental Monitoring (Including Microbiology Testing)
  • Disinfectant Efficacy Studies
  • Others
  • Patient And Site Recruitment
  • Technology
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • CNS Disorders
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Diabetes
  • Ophthalmology
  • Pain Management
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical
  • Small Molecules
  • Biologics
  • Medical Device
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Service
1.2.3. Therapeutic Area
1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Australia & New Zealand Healthcare CROs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Supportive Regulatory And Ethical Frameworks
3.2.1.2. Government Incentives And Investment in R&D And Advanced Infrastructure
3.2.1.3. Diverse Patient Pool
3.2.1.4. Cost-Effectiveness & Favorable Environment For Clinical Trials
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Concerns in CRO Services
3.2.2.2. Intellectual Property Rights Issues
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter’s Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Australia & New Zealand Healthcare CROs Market: Type Estimates & Trend Analysis
4.1. Australia & New Zealand Healthcare CROs Market, By Type: Segment Dashboard
4.2. Australia & New Zealand Healthcare CROs Market, By Type: Movement Analysis
4.3. Australia & New Zealand Healthcare CROs Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. Drug Discovery
4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Target Validation
4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Lead Identification
4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.4. Lead Optimization
4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Pre-Clinical
4.5.1. Pre-Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Clinical
4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. Phase I Trial Services
4.6.2.1. Phase I Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. Phase II Trial Services
4.6.3.1. Phase II Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. Phase III Trial Services
4.6.4.1. Phase III Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.5. Phase IV Trial Services
4.6.5.1. Phase IV Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Australia & New Zealand Healthcare CROs Market: Service Estimates & Trend Analysis
5.1. Australia & New Zealand Healthcare CROs Market, By Service: Segment Dashboard
5.2. Australia & New Zealand Healthcare CROs Market, By Service: Movement Analysis
5.3. Australia & New Zealand Healthcare CROs Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
5.4. Project Management/Clinical Supply Management
5.4.1. Project Management/Clinical Supply Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Data Management
5.5.1. Data Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Regulatory/Medical Affairs
5.6.1. Regulatory/Medical Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Medical Writing
5.7.1. Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Clinical Monitoring
5.8.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Quality Management/ Assurance
5.9.1. Quality Management/ Assurance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Bio-statistics
5.10.1. Bio-statistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Investigator Payments
5.11.1. Investigator Payments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12. Laboratory
5.12.1. Laboratory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.2. Sterility Testing
5.12.2.1. Sterility Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.3. Container/Closure Testing
5.12.3.1. Container/Closure Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.4. Extractables and Leachable Testing
5.12.4.1. Extractables and Leachable Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.5. Environmental Monitoring (Including Microbiology Testing)
5.12.5.1. Environmental Monitoring (Including Microbiology Testing) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.6. Disinfectant Efficacy Studies
5.12.6.1. Disinfectant Efficacy Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12.7. Others
5.12.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.13. Patient and Site Recruitment
5.13.1. Patient and Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.14. Technology
5.14.1. Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.15. Others
5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Australia & New Zealand Healthcare CROs Market: Therapeutic Area Estimates & Trend Analysis
6.1. Australia & New Zealand Healthcare CROs Market, By Therapeutic Area: Segment Dashboard
6.2. Australia & New Zealand Healthcare CROs Market, By Therapeutic Area: Movement Analysis
6.3. Australia & New Zealand Healthcare CROs Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. CNS Disorders
6.5.1. CNS Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Infectious Diseases
6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Immunological Disorders
6.7.1. Immunological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Cardiovascular Diseases
6.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Respiratory Diseases
6.9.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Diabetes
6.10.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Ophthalmology
6.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Pain Management
6.12.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Others
6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Australia & New Zealand Healthcare CROs Market: End Use Estimates & Trend Analysis
7.1. Australia & New Zealand Healthcare CROs Market, By End Use: Segment Dashboard
7.2. Australia & New Zealand Healthcare CROs Market, By End Use: Movement Analysis
7.3. Australia & New Zealand Healthcare CROs Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
7.4. Pharmaceutical Companies
7.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. Small Molecules
7.4.2.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Biologics
7.4.3.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Medical Device Companies
7.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Key Participant Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
8.3. Company Profiles
8.3.1. Paraxel International Corporation
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Service Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. SGS SA
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Service Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. ICON plc
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Service Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. Thermo Fisher Scientific Inc.
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Service Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. Medpace Australia Pty. Ltd
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Service Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. Charles River Laboratories International, Inc.
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Service Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. IQVIA
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Service Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Novotech
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Service Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Laboratory Corporation of America Holdings
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Service Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Syneos Health
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Service Benchmarking
8.3.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us